| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 716.0 | 659.9 |
| Profit before tax | 170.9 | 142.8 |
| Net income | 137.5 | 111.1 |
| EPS (diluted, $ a share) | $4.84 | $3.86 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +23.7% |
|---|---|
| Revenue, year on year | +8.5% |
| Operating margin | 23.1% |
10-Q filed with the SEC, NASDAQ: MEDP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Medpace Holdings, Inc.: key numbers
- Share price
- $648.20Close, Nov 16
- Market cap
- $18.1B
- Shares outstanding
- 27.97MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Commercial Physical & Biological ResearchSIC 8731
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Medpace Holdings, Inc.
All →Medpace Holdings General Counsel & Corp. Secy. Stephen P. Ewald Sells $859K of Stock
Stephen P. Ewald, General Counsel & Corp. Secy., sold 1,245 shares of Medpace Holdings, Inc. at $690.00 a share, worth $859K in total on Oct 29, 2026. Shares held after the trade: 19,098 (-6.1%).
- Value
- $859K
- Shares
- 1,245
- Price
- $690.00
- Role
- General Counsel & Corp. Secy.
- Holding change
- -6.1%
- Trade date
- Oct 29, 2026
Medpace Holdings Exec. VP, Operations Susan E. Burwig Sells $13.5M of Stock
Susan E. Burwig, Exec. VP, Operations, sold 20,000 shares of Medpace Holdings, Inc. at $677.00 a share, worth $13.5M in total between Oct 26, 2026 and Oct 27, 2026. Shares held after the trade: 54,012 (-6.8%).
- Value
- $13.5M
- Shares
- 20,000
- Average price
- $677.00
- Role
- Exec. VP, Operations
- Holding change
- -6.8%
- Trade date
- Oct 26, 2026 to Oct 27, 2026
Medpace Holdings Financial Results
Medpace reported Q3 2026 revenue of $716.0 million, an 8.5% increase year-over-year, and GAAP net income of $137.5 million ($4.84 per diluted share). Alongside the results, the Board authorized a new $1.0 billion stock repurchase program effective through December 2028, replacing the previous authorization which had $527.0 million remaining.
Medpace Holdings President & CEO August J. Troendle Sells $30.3M of Stock
August J. Troendle, President & CEO, sold 48,667 shares of Medpace Holdings, Inc. at $621.02 to $625.47 a share (average $623.03) in 2 transactions, worth $30.3M in total between Sep 29, 2026 and Sep 30, 2026. Shares held after the trade: 338,225 (-6.1%).
- Value
- $30.3M
- Shares
- 48,667
- Average price
- $623.03
- Role
- President & CEO
- Holding change
- -6.1%
- Trade date
- Sep 29, 2026 to Sep 30, 2026
Medpace Holdings President & CEO August J. Troendle Sells $6.75M of Stock
August J. Troendle, President & CEO, sold 10,880 shares of Medpace Holdings, Inc. at $620.40 a share, worth $6.75M in total on Sep 17, 2026. Shares held after the trade: 504,273 (-2.1%).
- Value
- $6.75M
- Shares
- 10,880
- Price
- $620.40
- Role
- President & CEO
- Holding change
- -2.1%
- Trade date
- Sep 17, 2026